Literature DB >> 3498763

Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies.

G A van Seventer1, K C Kuijpers, R A van Lier, E R de Groot, L A Aarden, C J Melief.   

Abstract

The objective of this study was to elucidate the mechanism responsible for inhibition as well as induction of cytolytic activity in cytotoxic T lymphocytes (CTL) by cluster-defined 3 (T3) (CD3) monoclonal antibodies (mAb). A series of isotype heavy chain switch variants (murine IgG1, IgG2a, IgG2b, IgA, and IgE) of a single CD3 mAb was used in the analysis of effects of CD3 mAb on the cytolytic activity of an allospecific CTL clone. The results obtained indicate that the inhibition of cytolytic activity of CTL by CD3 mAb is not caused by interference with events that occur after conjugate formation, such as programming for lysis and the delivery of the lethal hit, but by inhibition of specific recognition of the target cell by the CTL. We also present evidence that induction of nonspecific CTL activity by CD3 mAb is only achieved by direct binding of the Fc receptor to the CD3 mAb. This observation allowed us to use the CD3 mAb-induced nonspecific cytolytic activity of CTL as a sensitive assay for detection of Fc receptors for various heavy chain isotypes. So far, evidence was found for human Fc receptors reactive with murine IgG1, IgG2a, and IgG2b, but not for murine IgA or IgE. The combined results indicate a similar role for Fc receptors in induction of cytolytic activity of CTL by CD3 mAb as well as in CD3 mAb-induced proliferative responses of T cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections.

Authors:  G Vanham; L Kestens; P Gigase; R Colebunders; M Vandenbruaene; L Brijs; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

2.  Inhibition of non-MHC-restricted cytotoxicity by CD45 but not CD3 monoclonal antibodies in patients with large granular lymphoproliferative disease.

Authors:  G C Starling; S E Davidson; J C Nimmo; M E Beard; D N Hart
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

3.  Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.

Authors:  Bohua Li; Hao Wang; Jianxin Dai; Junjie Ji; Weizhu Qian; Dapeng Zhang; Sheng Hou; Yajun Guo
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

4.  Regulation of clonal growth by anti-T-cell receptor antibody-directed lysis.

Authors:  P De Berardinis; M Londei; S Carrel; M Feldmann
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

5.  Anti-CD2 and anti-CD3 induced T cell cytotoxicity of human intraepithelial and lamina propria lymphocytes.

Authors:  J Rüthlein; G Heinze; I O Auer
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

6.  Relative increase of inflammatory CD4+ T cells in the cerebrospinal fluid of multiple sclerosis patients and control individuals.

Authors:  F T Rotteveel; B Kuenen; I Kokkelink; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

7.  Clonal analysis of functionally distinct human CD4+ T cell subsets.

Authors:  F T Rotteveel; I Kokkelink; R A van Lier; B Kuenen; A Meager; F Miedema; C J Lucas
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

8.  Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.

Authors:  Y Nakamura; Y Tokuda; M Iwasawa; H Tsukamoto; M Kidokoro; N Kobayashi; S Kato; T Mitomi; S Habu; T Nishimura
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

9.  Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.

Authors:  T Kikuchi; M Watanabe; T Ohno
Journal:  Jpn J Cancer Res       Date:  1991-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.